Latest Conference Articles

July 20th 2018, 7:11pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, as well as emerging immunotherapy treatment options in multiple myeloma.

July 20th 2018, 12:28am

Pan Pacific Lymphoma Conference

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in adult patients with Burkitt lymphoma.

July 20th 2018, 12:27am

Pan Pacific Lymphoma Conference

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the antibody drug conjugate polatuzumab vedotin in lymphoma.

July 20th 2018, 12:04am

Pan Pacific Lymphoma Conference

A retrospective study of patients with Hodgkin lymphoma found high rates of sequelae including pulmonary events and cardiovascular disease following frontline treatment with chemotherapy including bleomycin.

July 19th 2018, 11:01pm

Pan Pacific Lymphoma Conference

Steven M. Horwitz, MD, discusses the best strategy for the treatment of CD30-positive peripheral T-cell lymphomas.

July 19th 2018, 10:55pm

Pan Pacific Lymphoma Conference

Sarah Holstein, MD, PhD, discusses new approaches to induction therapy for patients with myeloma.

July 18th 2018, 10:30pm

Pan Pacific Lymphoma Conference

David G. Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses updates with CAR T-cell therapy in non-Hodgkin lymphoma.

July 18th 2018, 10:28pm

Pan Pacific Lymphoma Conference

Julie M. Vose, MD, MBA, professor, internal medicine, chief, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the importance of genomic analysis in patients with non-Hodgkin lymphoma.

July 18th 2018, 9:15pm

Pan Pacific Lymphoma Conference

Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring.

July 18th 2018, 8:59pm

Pan Pacific Lymphoma Conference

With promising data of brentuximab vedotin and inotuzumab ozogamicin leading the way, antibody-drug conjugates are beginning to make a greater impact on the lymphoma treatment landscape.

July 18th 2018, 7:08pm

Pan Pacific Lymphoma Conference

An effective lymphodepletion strategy is critical to success with chimeric antigen receptor T-cell therapy, but also the choice of patients and even the cells used for CAR T cell manufacturing should be made with care.

July 16th 2018, 9:32pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Javier A. Pinilla-Ibarz, MD, PhD senior member, Moffit Cancer Center, discusses the recent advances in chronic myeloid leukemia (CML). Pinilla-Ibarz says that he and colleagues do not expect much in the field after other recent advancements, but he is still surprised to see what is being concentrated on today.

July 16th 2018, 6:04pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses evidence supporting the use of a triplet regimen versus a doublet regimen in elderly and transplant ineligible patients with multiple myeloma.

July 15th 2018, 1:51am

PER® Annual Live Medical Crossfire: Hematologic Malignancies

With newer agents approved for patients with chronic lymphocytic leukemia, physicians are now challenged with how best to utilize them.

July 15th 2018, 1:38am

PER® Annual Live Medical Crossfire: Hematologic Malignancies

George F. Geils, Jr, MD, discussed the clinical efficacy and adverse event management techniques for pembrolizumab as a treatment for patients with classical Hodgkin lymphoma.

July 15th 2018, 12:12am

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Chimeric antigen receptor T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma, with research now exploring ways to shift these agents earlier in the treatment paradigm.

July 14th 2018, 11:13pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Gabriela S. Hobbs, MD, discusses how discontinuing tyrosine kinase inhibitors will change the treatment landscape and other strategies for treating patients with chronic myeloid leukemia.

July 14th 2018, 11:03pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Jacqueline D. Barrientos, MD, MS, CLL Research and Treatment Program, Northwell Health Systems, discusses the current challenges oncologists are faced with in the field of chronic lymphocytic leukemia.

July 14th 2018, 10:02pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements currently happening in the field of multiple myeloma.

June 22nd 2018, 11:01pm

ESMO Gastrointestinal Cancers Congress

Results from the regorafenib dose optimization study (ReDOS) presented at the 2018 World Congress on GI Cancer established that the strategy of escalating regorafenib from 80 mg to 160 mg per day was superior to starting at a dose of 160 mg per day.